Search Within

Carlyn Rose Tan

Formats
  1. Meeting Abstract (104)
  2. Journal Article (23)
  3. Research Letter (8)
  4. Correspondence (3)
  5. Review (3)
Groups
  1. Hematologic Malignancies, Division of (141)
  2. Department of Medicine (124)
  3. Center for Hematologic Malignancies (123)
  4. Myeloma (121)
  5. Survivorship Research (121)
  6. CTCR Scholars (120)

More Groups

People
  1. Alexander Lesokhin (119)
  2. Sham Mailankody (119)
  3. Urvi Shah (119)
  4. Malin Hultcrantz (118)
  5. Hani Hassoun (117)
  6. Neha Korde (117)

More People

Years
  1. 2025 (7)
  2. 2024 (44)
  3. 2023 (41)
  4. 2022 (29)
  5. 2021 (13)
  6. 2020 (7)
Publications
  1. Blood (54)
  2. Clinical Lymphoma, Myeloma and Leukemia (41)
  3. Journal of Clinical Oncology (9)
  4. Blood Cancer Journal (6)
  5. Blood Advances (5)
  6. American Journal of Hematology (4)

More Publications

Publishers
  1. American Society of Hematology (59)
  2. Elsevier Inc. (43)
  3. American Society of Clinical Oncology (9)
  4. Nature Publishing Group (8)
  5. John Wiley & Sons, Inc. (4)
  6. Taylor & Francis Group (3)

More Publishers

Results (141)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes offrailty subgroups treated with teclistamab in the real-world: An International Myeloma Foundation study database analysis
    Meeting Abstract

    Mian, H.; Tan, C. R.; Asoori, S.; Popat, R.; Abdallah, N.; Chhabra, S.; Parrondo, R. D.; Pond, G. R.; Martin, T.; Durie, B. G. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Evaluation of the safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment
    Meeting Abstract

    Terpos, E.; Ntanasis-Stathopoulos, I.; Kyriakou, C.; Tan, C.; Abildgaard, N.; Delforge, M.; Fantl, D.; Usmani, S.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save